In high-risk group, such as lymph node metastasis or large tumor size, the gap in DFS became wider with higher protein expression, especially HER2 and ERCC1 (Supplementary Figure 2). The gene discussed is ERCC1; the disease is metastatic malignant neoplasm in the lymph nodes.